From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Features

General Medicine: Features

Some content may require paid access to the site. Subscribe or purchase a seven-day site pass for the full text of all our clinical perspectives on medical journal articles, guidelines, and news.


to
Items 51-60 of 79 are shown

FEATURE: CHRONIC FATIGUE: NEW INSIGHTS, OLD MYSTERIES

Chronic fatigue syndrome (CFS) continues to inspire interest and controversy. The Centers for Disease Control and Prevention recently updated the case definition (Ann Intern Med . . .

FEATURE: WHAT'S THE BEST WAY TO WEAN FROM THE VENTILATOR?

For years, clinicians have debated the best way to wean patients from ventilators when acute respiratory failure has resolved. Two studies recently addressed this question, . . .

FEATURE: DOES PNEUMOCOCCAL VACCINE LIVE UP TO ITS REPUTATION?

Because pneumococcal vaccination seems to have avoided the scrutiny imposed on a variety of other preventive services, one might infer that its efficacy in preventing . . .

FEATURE: DO WOMEN IN THEIR 40s NEED MAMMOGRAMS?

Perhaps no current issue in preventive medicine has sparked more debate than the value of mammographic screening for women in their 40s. Since the 1960s, . . .

FEATURE: STROKE PREVENTION IN AF: A SECOND LOOK

Chronic nonrheumatic atrial fibrillation (AF) affects 2 to 3 percent of people aged 55 to 64 and about 12 percent of those over 75. It . . .

FEATURE: WHICH FIRST-LINE DRUG FOR HYPERTENSION?

Early in 1993, the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure -- representing numerous professional groups and federal agencies -- . . .

FEATURE: ERYTHROPOIETIN: WHEN IS IT APPROPRIATE

The synthesis of several kinds of growth factors, most notably erythropoietin (EPO), has revolutionized the management of certain hematologic conditions. EPO has been used primarily . . .

FEATURE: THROMBOLYTIC WARS: NEW DATA FUEL CONTROVERSY AND CONSENSUS

When the results of the large GUSTO trial were published last September, a question that some considered settled became a front-page controversy once again. Which . . .

SPECIAL FEATURE: THE TOP MEDICAL STORIES OF 1993

During 1993, Journal Watch reported many exciting and important advances. As the new year begins, the Editors have chosen what we believe are the developments . . .

FEATURE: THE PROMISE AND PITFALLS OF SUMATRIPTAN

Treatments for migraine headache abound, but most are plagued by side effects and limited efficacy. Last December, the U.S. Food and Drug Administration approved sumatriptan . . .

Items 51-60 of 79 are shown

to

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?





Copyright © 2013. Massachusetts Medical Society. All rights reserved.